Navigation Links
OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Vice President and Controller, Veronica Vallejo has been promoted to Chief Financial Officer effective February 8, 2013.


"Veronica has been an integral part of our team since the inception of OncoSec and this promotion is well deserved. Her strategic insights and strong financial acumen will be valuable to the future success and growth of the company," said Punit Dhillon , President and CEO.

Veronica has over fifteen years of public accounting experience and has worked for nearly a decade in a senior management position. She has extensive experience in public company operations and all financing and accounting functions. Veronica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University.  She is a certified public accountant and a member of the American Institute of Certified Public Accountants.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
2. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
3. OncoSec Medical Announces $7.2 Million Public Offering
4. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
5. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
6. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
7. OncoSec to Present at Upcoming Healthcare and Investor Conferences
8. OncoSec Granted New Patent from China
9. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
10. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
11. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 The ... to repeated failure of IVF cycles. After failure of ... dejected and had lost all hopes that she would be able to ... miracle child conceived after failure of over 15 IVF ... (UK) before they decided to take one last attempt with Gaudium ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... bunion treatment, is offering lower prices in an early celebration of the early ... the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety ... Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ ... the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during ...
(Date:11/24/2015)... ... , ... DMG Productions announced that they will feature Aphria, Inc., in an ... Channel. Dates and show times TBA. , Aphria, Inc., is a publicly traded company ... and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). ...
Breaking Medicine News(10 mins):